In one study using transcriptomic data obtained from TCGA and METABRIC cohorts, high AR levels in ER+ BC correlated with fewer tumor-infiltrating lymphocytes and cytolytic activity, as well as far less sensitivity to neoadjuvant chemotherapy, yet better survival (45). The gene discussed is ESR1; the disease is breast cancer.